ALS Nexus 2026: Uniting Hope, Science, and Strategy Against ALS

ARLINGTON, Va. – August 18, 2026 – As the global ALS community prepares to gather in Orlando and online, a palpable sense of urgency hangs in the air. For those affected by amyotrophic lateral sclerosis (ALS)—a relentless neurodegenerative disease that methodically strips away a person's ability to move, speak, and breathe—time is the most precious and finite resource. It is this urgency that The ALS Association aims to channel into tangible progress with its premier annual conference, ALS Nexus, returning from August 23-26.

The four-day event is more than a series of presentations; it is a critical intersection point for the disparate worlds fighting this disease. Researchers deep in the complexities of gene therapy, clinicians on the front lines of patient care, advocates navigating bureaucratic mazes, and, most importantly, people living with ALS and their families will all converge. The goal is not just to share information, but to forge the collaborations needed to accelerate the journey from scientific discovery to meaningful clinical impact.

"For people living with ALS, time is everything — and ALS Nexus is where we turn that urgency into progress," said ALS Association President and CEO Calaneet Balas in a statement. "When families, researchers, clinicians, and advocates are all in one room pulling in the same direction, ideas move faster and no one fights this disease alone. That's how we get closer to making ALS livable and curing it."

A Confluence of Hope and Humanity

In a field defined by daunting scientific challenges and profound personal loss, the conference is placing a deliberate emphasis on the human spirit. The keynote session, titled "Finding Hope," moves beyond academic discourse to explore resilience itself as a critical component of the ALS journey. The session features a fireside chat between Balas and acclaimed actress and author Tabitha Brown, who brings a deeply personal perspective after losing her mother to the disease.

Brown’s presence underscores a fundamental truth about the modern fight against complex diseases: it requires both scientific rigor and profound empathy. Her message, grounded in faith and joy amidst struggle, aims to resonate with every stakeholder, from the lab technician to the primary caregiver. Following this intimate conversation, the session will pivot to the clinical, with Dr. Richard Bedlack and Dr. Peggy Plews-Ogan presenting on hope as a measurable and personalized component of care. This unique pairing—a celebrity advocate and clinical experts—is a microcosm of the conference itself, bridging the gap between lived experience and medical practice to build a more holistic support system.

Charting the Future of ALS Research

While hope provides the fuel, science provides the engine. ALS Nexus 2026 arrives at a pivotal moment for ALS research. The landscape has been transformed in recent years by breakthroughs that were once the stuff of speculation. The 2023 approval of Tofersen (Qalsody) for SOD1-mutated ALS was a watershed moment, validating the promise of gene-targeted therapies and the use of biomarkers like neurofilament light chain (NfL) to track disease progression. With Qalsody now approved in major global markets and Japan’s 2024 approval of Rozebalamin to slow functional decline, the therapeutic pipeline is more robust than ever.

This year’s conference will spotlight the next wave of innovation. A session on "Emerging Science" features a new generation of researchers whose work is often driven by personal connection to the disease. Dr. Jill Goslinga of UC San Francisco, who resolved to study ALS after her father’s diagnosis in her teens, will present alongside peers from Johns Hopkins and Harvard. Their research represents the leading edge of a field increasingly focused on precision medicine, targeting mechanisms like the TDP-43 protein misfolding implicated in up to 97% of all ALS cases. With therapies like VectorY's VTx-002 receiving FDA Fast Track status and adaptive platform trials like HEALEY-ALS accelerating the testing process, the insights shared at Nexus could help shape clinical trials and investment for years to come.

Experts note that the future of ALS treatment will likely involve a multi-pronged, personalized approach rather than a single silver bullet. The conference is a key venue for aligning the research community around this vision, fostering collaboration on everything from identifying new biomarkers to designing more efficient clinical trials that can deliver answers faster.

Confronting the System: Beyond the Diagnosis

For a person diagnosed with ALS, the battle is fought on two fronts: one against the disease inside their body, and another against the external systems that can either facilitate or obstruct their access to care. A breakthrough therapy is of little use if it’s tied up in administrative red tape. Recognizing this, ALS Nexus is dedicating a prime session to one of the most frustrating and pragmatic challenges: insurance denials.

The session, "Winning Appeals: Navigating Insurance Barriers in ALS Care," speaks directly to a growing crisis within the community. As new, often expensive, treatments emerge, and as the complexity of care increases, patients and clinicians alike report spending an inordinate amount of time fighting for coverage. These delays are not mere inconveniences; in a disease where progression is measured in weeks and months, a stalled approval can mean an irreversible loss of function.

This session aims to arm the entire community—clinicians, patients, and advocates—with practical, field-tested strategies to break through these barriers. From crafting effective appeal letters to leveraging clinical documentation, the focus is on actionable tools that can reduce administrative burden and ensure patients receive the interventions they need. By placing this topic on its main agenda, the conference elevates a systemic issue to the same level of importance as basic science, affirming that true progress requires improving the entire ecosystem of care, not just the science within the lab.

From Urgency to Action: A Unified Front

The ALS Association, as the world’s largest organization dedicated to the disease, is leveraging its position to create a powerful feedback loop. By funding global research, supporting a nationwide network of care centers, and advocating for better public policy, the organization builds the infrastructure that makes an event like ALS Nexus possible. The knowledge, connections, and strategies developed in Orlando will, in turn, be disseminated through this network, amplifying their impact.

This work is more critical than ever. Recent studies project a significant increase in ALS prevalence by 2040, driven by an aging global population. This demographic shift adds another layer of urgency to the search for treatments and the need to build sustainable systems of care. The conference’s recognition of "ALS Heroes"—individuals nominated by the community for their unwavering dedication—serves as a poignant reminder that this monumental effort is built on the passion and resilience of countless individuals.

The ultimate measure of the conference's success will be the progress that follows. It will be measured in the new collaborations sparked between labs, the new strategies clinicians take back to their practices, the renewed sense of empowerment felt by families, and the collective resolve to accelerate the mission to make ALS a livable disease until it can be cured.